CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02616 CSTONE PHARMA-B

Not Yet Opened 12-15 16:08:35

5.900

-0.220

-3.59%

High6.010	Low5.770	Vol7.80M
Open6.000	D1 Closing6.120	Amplitude3.92%
Mkt Cap8.71B	Tradable Cap8.71B	Total Shares1.48B
T/O45.64M	T/O Rate0.53%	Tradable Shares1.48B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"CSTONE PHARMA-B","latestPrice":5.9,"timestamp":1765786115008,"preClose":6.12,"halted":0,"volume":7798500,"delay":0,"floatShares":1476000000,"shares":1476000000,"eps":-0.07899072025120425,"marketStatus":"Not Yet Opened","change":-0.22,"latestTime":"12-15 16:08:35","open":6,"high":6.01,"low":5.77,"amount":45640700,"amplitude":0.039216,"askPrice":5.9,"askSize":84000,"bidPrice":5.87,"bidSize":9500,"shortable":3,"etf":0,"ttmEps":-0.32254258573085026,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":0,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":6.12,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0.713705,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616/tweets","defaultTab":"tweets","newsList":[{"id":"2591974456","title":"CStone Pharmaceuticals (SEHK:2616): Valuation Check After GAVRETO Wins China National Reimbursement Drug List Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2591974456","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591974456?lang=en_us&edition=fundamental","pubTime":"2025-12-15 06:15","pubTimestamp":1765750505,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) just secured a key regulatory win, with its RET-targeting cancer drug GAVRETO set to join China’s National Reimbursement Drug List from January 2026. This change could reshape both patient access and long term revenue visibility.\nSee our latest analysis for CStone Pharmaceuticals.\nThe market seems to be warming up to that story already, with a 1 month share price return of 11.48 percent and a powerful year to date share price gain of 149.8 percent, even...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-check-after-gavret","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-check-after-gavret","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1574","BK1161","02616","NHLD"],"gpt_icon":0},{"id":"2591551816","title":"Why CStone Pharmaceuticals (SEHK:2616) Is Up 7.9% After GAVRETO NRDL Inclusion Approval In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2591551816","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591551816?lang=en_us&edition=fundamental","pubTime":"2025-12-13 22:23","pubTimestamp":1765635780,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals announced that its RET-targeted cancer therapy GAVRETO® (pralsetinib) has been approved for inclusion in China’s National Reimbursement Drug List, with reimbursement due to begin on 1 January 2026.\nThis listing materially broadens patient access in China’s public healthcare system, potentially reinforcing CStone’s role as a key oncology player in Greater China.\nWe’ll now examine how NRDL inclusion for GAVRETO shapes CStone’s investment narrative, particularly around...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/why-cstone-pharmaceuticals-sehk2616-is-up-79-after-gavreto-n","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/why-cstone-pharmaceuticals-sehk2616-is-up-79-after-gavreto-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"1119946536","title":"CStone Pharma-B (02616) Rises Over 5% as Pralsetinib Included in National Reimbursement List; Company Expands 2.0 Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1119946536","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119946536?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:14","pubTimestamp":1765509254,"startTime":"0","endTime":"0","summary":"CStone Pharma-B (02616) surged more than 5%, reaching HK$6.07 by the time of writing, with a trading volume of HK$22.70 million. The increase follows the company's announcement that its RET...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"1123300626","title":"HK Movers | Biomedical Stocks Jump With Xuanzhu Biopharmaceutical up 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123300626","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123300626?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:25","pubTimestamp":1765506351,"startTime":"0","endTime":"0","summary":"Biomedical stocks jumped in Hong Kong. Xuanzhu Biopharmaceutical rose 22%; Joinn Laboratories rose 11%; Jacobio Pharmaceuticals rose 6%; CStone Pharmaceuticals rose 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7432cf6f68b776bebe5e689173bcab7f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","02616","02575","06127"],"gpt_icon":0},{"id":"1114031659","title":"Non-Executive Director Hu Zhengguo Increases Stake in CStone Pharma-B (02616) by 1 Million Shares at HK$5.75 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1114031659","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114031659?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:24","pubTimestamp":1765193055,"startTime":"0","endTime":"0","summary":"On December 4, non-executive director Hu Zhengguo purchased 1 million shares of CStone Pharma-B (02616) at HK$5.7546 per share, totaling HK$5.7546 million, according to the latest data from the Hong...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2589890683","title":"CStone Pharmaceuticals' Cancer Therapy Drug Added to China's Reimbursement List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589890683","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589890683?lang=en_us&edition=fundamental","pubTime":"2025-12-08 13:45","pubTimestamp":1765172732,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  said its targeted cancer drug Gavreto  has been included in China's 2025 National Reimbursement Drug List, according to a Monday Hong Kong bourse filing.The therapy, approved in China for RET fusion-positive non-small cell lung cancer, and for RET-mutant medullary thyroid carcinoma and RET fusion-positive thyroid cancer in patients aged 12 and above requiring systemic therapy, will be reimbursable nationwide from Jan. 1, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"1147568727","title":"CSTONE PHARMA-B (02616): Pralsetinib Capsules (Gavreto®) Included in China's 2025 National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1147568727","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147568727?lang=en_us&edition=fundamental","pubTime":"2025-12-08 12:24","pubTimestamp":1765167863,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) announced that its product Pralsetinib Capsules (Gavreto®, 100 mg) has been included in the latest edition of China's National Reimbursement Drug List (NRDL) released by the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU1102505762.USD","BK1100","BK1221","LU0228659784.USD","BK1160","SG9999015945.SGD","BK1209","LU0572944931.SGD","LU1969619763.USD","BK1158","BK1606","LU0048575426.USD","LU0164872284.USD","LU1497733557.USD","LU0039217434.USD","LU0594300419.USD","LU2543165471.USD","06168","03998","02020","01939","BK1556","06657","IE00BQXX3D17.EUR","03658","IE00BQXX3C00.GBP","IE00BGV7N243.SGD","LU0540923850.HKD","SGXZ62798434.SGD","01530","BK1589","LU2357125470.USD","SGXZ86797644.SGD","BK1207","09877","LU0737861699.HKD","02451","BK1155","BK1554","SG9999014674.SGD","01093","02469","LU0345776255.USD","LU0823426480.USD","03800","HK0000252152.HKD","LU1720050803.USD","LU0708995583.HKD","LU1861219969.SGD","LU1366334651.USD","06633","LU0348825331.USD","LU2476274308.USD","01119","BK1527","HK0000306701.USD","LU0164865239.USD","BK1117","LU0509642566.USD","LU1224709979.USD","09660","BK1125","BK1214","LU1039395188.USD","09699","BK1516","80020","LU0823038988.USD","06090","BK1524","BK1617","IE00B8L5B284.USD","LU0175139822.USD","SG9999004311.SGD","LU1267930227.SGD","BK1608","02177","BK1591","LU0067412154.USD","LU1226288253.USD","LU1880383440.USD","LU0541502299.USD","LU1939255532.USD","LU0823397103.USD","01739","SG9999015986.USD","HK0000320223.HKD","LU1048588211.SGD","BK1604","LU0456827905.SGD","SG9999001226.SGD","LU1880383366.USD","02565","LU1235295612.USD","03709","BK1258","01384","SG9999015952.SGD","LU0310800965.SGD","LU0348827113.USD","LU1522347837.USD","LU1152091754.HKD","LU0348767384.USD","82331","00384","BK1190","03145","BK1195","LU0463099449.HKD","09690","00460","01519","BK1557","01880","002594","LU0880133367.SGD","LU1211504680.USD","06609","02392","LU0128525689.USD","LU1960683339.HKD","BK1227","00451","BK1164","00992","02331","06862","LU0561508036.HKD","BK1239","BK1240","IE0034224299.USD","02298","BK1571","LU0082770016.USD","LU0289739343.SGD","LU1497733631.SGD","BK1193","06996","03396","LU1981816686.USD","BK1542","HK0000252160.HKD","IE00BVYPNP33.GBP","LU0348805143.USD","SG9999001051.SGD","IE00B0JY6N72.USD","LU0370786039.SGD","06069","06186","01783","IE00BYV24P56.USD","LU0048580855.USD","LU0469268626.HKD","LU0314109678.HKD","00826","BK1520","ANPDY","02886","BK1564","BK1119","LU0164939612.USD","00305","LU0516422440.USD","LU0593848301.USD","01818","02145","BK1222","BK1574","BK1509","LU1226287875.USD","LU0605514214.HKD","09990","LU1008478684.HKD","02629","LU1102505929.USD","IE00BPRC5H50.USD","LU2097828631.EUR","LU2778985437.USD","02121","LU1861214812.USD","LU0819123356.HKD","BK1212","09955","IE0009570106.USD","01177","BK1178","00017","BK1237","06138","LU0634319403.HKD","LU0828237510.HKD","LU1188198961.HKD","BK1225","SG9999001903.USD","01440","02509","03680","02155","BK1541","BK1147","LU0501845795.SGD","BK1230","BK1521","09890","02171","SG9999015978.USD","01640","01211","02420","LU0511384066.AUD","LU0543330566.HKD","BK1179","09923","BK1502","LU0269904917.USD","IE00BZ08YT58.USD","BK1143","BK1515","LU2449936058.SGD","01907","02650","LU1366334578.USD","LU0417516902.SGD","BK1257","IE0003851619.USD","LU1675838814.USD","01735","BK1124","01952","02142","LU1956131251.USD","IE00BZ08YS42.EUR","LU2153592121.USD","LU0871576103.HKD","LU1023057109.AUD","06100","02419","LU0823414478.USD","LU0348783233.USD","BK1141","LU2097828805.USD","LU1634259391.SGD","00267","LU1226287529.USD","LU0214875030.USD","LU0516422952.EUR","LU0650527681.SGD","06618","LU0052756011.USD","LU0320764599.SGD","IE0003795394.USD","BK1253","IE00BZ08YR35.GBP","BK1613","LU0417516738.SGD","LU2663582299.SGD","01164","02268","LU2177674079.SGD","BK1168","LU1794554557.SGD","LU0011963245.USD","LNNGY","LU0261950470.USD","LU0588545490.SGD","01520","LU0856984785.SGD","LU0762540952.USD","09878","02380","BK1616","00382","LU0516422366.SGD","LU0072462343.USD","01809","LU0868486357.SGD","BK1544","LU3063872942.SGD","LU0516423091.SGD","LU2328871848.SGD","BK1593","HYDD.SI","LU1303224171.USD","LU0165289439.USD","01405","LU0164880469.USD","BK1560","06855","LU0499858602.USD","03677","09911","06608","02150","LU0828238088.HKD","BK1128","09678","LU0516423174.USD","SG9999002828.SGD","LU0737861772.HKD","LU0259732245.USD","BK1114","BK1200","BK1161","09926","02158","BK1597","BK1522","LU0702159699.USD","BK1566","02276","BK1134","02567","IE00B031HY20.USD","BK1183","BK1610","LU0052750758.USD","02696","01448","LU0326950275.SGD","01458","LU1868837565.USD","00135","09639","06677","00875","SG9999002950.SGD","LU1328615791.USD","HK0000306685.HKD","LU1166156734.SGD","LU1497734951.SGD","LU2045819591.USD","01117","BK1229","03836","LU1961090484.USD","09927","LU1481107354.HKD","02057","BK1618","LU2023250504.SGD","LU1226287792.SGD","LU1770036033.HKD","LU0572939691.SGD","03738","BK1539","SG9999011746.SGD","02595","LU0054450605.USD","IE00B5MMRT66.SGD","06683","00855","LU2242644610.SGD","BK1096","BK1609","LU1868838027.USD","LU2238339852.HKD","LU2294711713.HKD","02273","SG9999001069.SGD","LU2106854487.HKD","SG9999000459.SGD","IE00B543WZ88.USD","LU1770034418.SGD","00999","BK1111","09996","LU2097828557.USD","IE00BVYPNQ40.USD","LU2476274720.SGD","06919","BK1512","LU0823414551.USD","LU1282649067.USD","BK1531","BK1619","LU0287142896.SGD","LU0823426308.USD","00363","LU0315179316.USD","LU0431992006.USD","BK1559","BK1553","LU1868837722.USD","BK1144","LU0455707207.USD","02250","LU0327786744.USD","02460","IE0008369823.USD","LU0329678170.USD","LU0449515922.USD","LU0149721374.USD","LU0572940350.SGD","02096","BK1126","BK1220","LU0244354667.USD","BK1592","03896","LU0348735423.USD","LU1807302812.USD","LU0251143458.SGD","LU2249611893.SGD","LU1282649810.SGD","LU2039709279.SGD","LU1328277881.USD","01276","02157","00003","BK1110","02256","BK1578","LU0588545904.SGD","02411","LU0488056044.USD","BK1139","LU1242518931.SGD","LU0502904849.HKD","BK1528","LU0359201885.HKD","01833","BK1575","00960","02858","LU0289960550.SGD","LU0611395673.USD","LU0251144936.SGD","01333","BK1233","BK1163","BK1228","LU1974910355.USD","BK1518","BK1109","02167","06988","02552","03650","LU0048597586.USD","LU1993786604.SGD","09636","HK0000500386.USD","02556","BK1104","BK1594","03681","BK1526","LU2348773727.SGD","01651","BK1549","BK1540","BK1548","LU0449509016.USD","LU2008162690.USD","BK1167","LU0315178854.USD","82020","LU0620787316.HKD","02018","01969","02616","LU0819121731.USD","LU0289961442.SGD","00699","LU2360107325.USD","02598","BK1127","BK1188","BK1583","LU0211977185.USD","SG9999004220.SGD","LU2506952253.HKD","LU2153591404.USD","02315","02100","BK1550","LU0588546209.SGD","LU0791591158.USD","00656","IE00BQXX3F31.USD","LU0072913022.USD","LU2399975544.HKD","02279","IE00B0169L03.USD","LU0417516571.SGD","SG9999006597.SGD","BK1169","01585","LU0107464264.USD","BK1215","BK1504","BK1216","LU0348784397.USD","LU0307460666.USD","LU0348766576.USD","IE00B031J352.USD","LU0229945570.USD","LU0505663152.USD","LU0531971595.HKD","09919","02525","LU0140636845.USD","LU0143863784.USD","LU1634259557.SGD","BK1142","LU0359201612.USD","BK1194","LU0541501648.USD","00302","BK1595","LU1251922891.USD","BK1586","LU0254981946.USD","BK1555","02228","LU0791590937.USD","BK1590","00777","06821","02511","01762","81211","SG9999003461.SGD","00798","06060","LU0054237671.USD","LU0173614495.USD","02551","09860","LU0084288322.USD","01070","09961","01911","BK1607","BK1151","BK1095","IE00B29SXG58.USD","LU2506951792.HKD","00136","02197","LU1242518857.USD","BK1171","02533","LU0231483743.USD","BK1582","06086","LU0823437842.USD","BK1530","LU0823397285.USD","LU0384037296.USD","BK1219","BK1579","LU1831875114.USD","BK1224","BK1598","LU0499858438.USD","09880","01378","BK1615","09959","BK1148","02488","IE00BD6J9T35.USD","LU0831093199.SGD","LU0261947096.USD","IE00B8HQ1Z84.USD","LU2298064838.USD","02105","BK1175","LU0264606111.USD","IE0008368742.USD","86618","BYDDY","LU2460026573.USD","01471","SG9999000475.SGD","BK1500","SG9999002562.SGD","BK1519","LU1115378108.SGD","LU0823039010.USD","80992","01773","LU1951186391.HKD","BK1136","SG9999000418.SGD","SG9999006514.SGD","BK1140","BK1588","LNVGY","BK1154","BK1585","01877","00666","02587","BK1600","LU1046422090.SGD","LU2348774022.SGD","BK1605","BK1197","LU0865486749.SGD","LU1152091168.USD","00861","LU2125910500.SGD","LU0456846285.SGD","02670","IE00BGHQDM52.EUR","BK1186","SG9999002463.SGD","02382","LU1917777945.USD","LU2097828714.EUR","HK0000165453.HKD","00512","BK1131","LU0345775950.USD","BK1247","BK1137","BK1150","SGXZ90724238.SGD","LU2097828474.EUR","02400","BK1198","02013","BK1189","LU1808992512.USD","LU1719994722.HKD","01600","02431","LU0043850808.USD","LU0640798160.USD","02190","02436","01681","LU0531970944.HKD","02506","BK1596","LU0979878070.USD","LU0588545730.USD","IE0032431581.USD","BK1235","06160","BK1552","LU0594300179.USD","09956","BK1587","SG9999001093.SGD","LU1813983027.USD","01318","IE0031814852.USD","LU0261950983.USD","LU1508157978.USD","IE00BMCWC346.EUR","LU0274383008.USD","02498","LU0359202008.SGD","06963","00884","LU0082770016.SGD","BK1191","00300","06913","00020","BK1577","09992","BK1116","06058","02889","LU0143863198.USD","03939","BK1170","BK1184","LU0051755006.USD","LU2424517915.HKD","00867","HK0000320264.USD","LU1226288170.HKD","06613","02453","09985","02590","LU0049112450.USD","LU0329678337.USD","BK1523","02627","BK1132"],"gpt_icon":1},{"id":"2587731271","title":"CStone Pharmaceuticals (SEHK:2616) Is Up 9.7% After EC Approval for Sugemalimab in Lung Cancer—Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587731271","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587731271?lang=en_us&edition=fundamental","pubTime":"2025-11-29 00:15","pubTimestamp":1764346521,"startTime":"0","endTime":"0","summary":"On November 25, 2025, CStone Pharmaceuticals announced that the European Commission approved sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer characterized by specific genetic profiles and stable disease following platinum-based chemoradiotherapy.\nThis regulatory milestone not only broadens sugemalimab's reach into the European market, but also highlights the growing importance of targeted immunotherapies for difficult-to-treat...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-is-up-97-after-ec-approval-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-is-up-97-after-ec-approval-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","EC","BK4201","02616"],"gpt_icon":0},{"id":"1183957986","title":"HK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves Sugemalimab for Stage III NSCLC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1183957986","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183957986?lang=en_us&edition=fundamental","pubTime":"2025-11-27 13:46","pubTimestamp":1764222376,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) surged nearly 7% intraday, and as of press time, it was up 5.22% at HK$6.25, with a turnover of HK$39.03 million. The catalyst behind the rally is the announcement that the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4134","III","BK1161","02616"],"gpt_icon":0},{"id":"1187055363","title":"HK Stock Movement | CSTONE PHARMA-B (02616) Rises Over 5% as EU Approves New Indication for Sugemalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1187055363","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187055363?lang=en_us&edition=fundamental","pubTime":"2025-11-26 10:02","pubTimestamp":1764122533,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) surged more than 5%, reaching HK$5.94 by the time of writing, with a trading volume of HK$8.23 million. The uptick follows the announcement on November 25 that the European...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"1129350283","title":"CStone Pharmaceuticals-B (02616): Sugemalimab Approved by European Commission for Stage III NSCLC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1129350283","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129350283?lang=en_us&edition=fundamental","pubTime":"2025-11-25 12:14","pubTimestamp":1764044057,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) announced that the European Commission (EC) has approved a new indication for sugemalimab: as a monotherapy for adult patients with unresectable Stage III non-small...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2586445803","title":"European Commission Approves CStone's Sugemalimab for Stage III Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586445803","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586445803?lang=en_us&edition=fundamental","pubTime":"2025-11-25 12:05","pubTimestamp":1764043544,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals announced that the European Commission  has approved a new indication for sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer  who have PD-L1 expression on ≥1% of tumor cells, no sensitizing EGFR mutations, or ALK, ROS1 genomic aberrations, and whose disease has not progressed following platinum-based chemoradiotherapy. This approval follows the initial EC approval for sugemalimab in first-line NSCLC treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on November 25, 2025, and is solel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL5gWZXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2586870445","title":"CStone Pharmaceuticals - European Commission Approved Sugmalimab for Stage Iii Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586870445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586870445?lang=en_us&edition=fundamental","pubTime":"2025-11-25 12:05","pubTimestamp":1764043534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X00PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2585956911","title":"Can CStone Pharmaceuticals' (SEHK:2616) Novel Antibody Drive a New Era in Allergy Treatment Innovation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2585956911","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585956911?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:27","pubTimestamp":1763688464,"startTime":"0","endTime":"0","summary":"On November 7, 2025, CStone Pharmaceuticals presented promising preclinical data on its novel bispecific antibody, CS2015, at the ACAAI Annual Scientific Meeting in Orlando, showcasing its dual targeting of OX40L and TSLP in type 2 inflammation diseases.\nThis marks the first time CS2015 has been presented at an international conference, highlighting potential advancements in therapies for allergies, asthma, and related conditions.\nWe'll now explore how the innovative attributes of CS2015...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/can-cstone-pharmaceuticals-sehk2616-novel-antibody-drive-a-n","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/can-cstone-pharmaceuticals-sehk2616-novel-antibody-drive-a-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"1146436128","title":"Yang Jianxin Increases Stake in CSTONE PHARMA-B (02616) with 40,000 Shares at HK$6.14 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1146436128","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146436128?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:24","pubTimestamp":1763465050,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange shows that on November 14, Yang Jianxin purchased an additional 40,000 shares of CSTONE PHARMA-B (02616) at HK$6.14 per share, totaling HK$245,600....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"1117424956","title":"Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast","url":"https://stock-news.laohu8.com/highlight/detail?id=1117424956","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117424956?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:56","pubTimestamp":1763427395,"startTime":"0","endTime":"0","summary":"As the fourth technological revolution sweeps across the globe, with AI and large model technologies reaching critical breakthroughs, capital engines are driving the revaluation of Chinese assets at...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00003","00604","BK1531","02488","02268","02096","BK1147","BK1116","BK1506","LU1808992512.USD","01651","02533","SG9999003461.SGD","BK1583","BK1109","BK1175","SG9999015986.USD","BK1586","BK1224","IE00BGHQDM52.EUR","BK1221","LU0348767384.USD","BK1104","09678","06919","00290","BK1216","BK1163","BK1183","BK1193","06609","LU1522347837.USD","02587","IE00BVYPNP33.GBP","09959","BK1552","00382","02453","LU0348825331.USD","02616","01907","BK1139","BK1518","LU2476274308.USD","BK1619","02171","03658","LU2778985437.USD","06677","BK1539","LU0417516902.SGD","02561","BK1209","02411","BK1207","02670","BK1131","BK1591","BK1124","09878","HK0000252152.HKD","02431","SG9999015945.SGD","BK1575","00302","06090","HK0000500386.USD","01681","BK1542","BK1574","LU2488822045.USD","00855","IE00B5MMRT66.SGD","01333","02509","BK1556","LU1497733631.SGD","LU1497733557.USD","BK1095","BK1527","SG9999014674.SGD","BK1608","06633","BK1191","BK1171","02551","02177","BK1594","BK1137","BK1194","BK1225","06660","BK1593","LU0348766576.USD","00826","BK1529","02886","02380","BK1114","01762","BK1592","BK1587","SG9999001069.SGD","IE00BMCWC346.EUR","00552","09860","09911","BK1500","SG9999002950.SGD","01969","06996","BK1258","BK1125","06100","BK1606","01773","BK1229","01318","BK1516","BK1618","02567","02858","BK1555","LU1497734951.SGD","BK1577","00305","BK1155","IE00B543WZ88.USD","BK1609","IE00BVYPNQ40.USD","00861","BK1186","09996","BK1144","BK1613","IE00BYV24P56.USD","00196","LU2460026573.USD","LU1634259557.SGD","BK1150","02256","02167","BK1582","BK1228","BK1100","BK1524","BK1178","SG9999015978.USD","00699","BK1142","BK1579","BK1578","IE00BPRC5H50.USD","02142","BK1132","00867","BK1585","BK1141","09919","BK1140","01228","02157","06069","BK1202","02420","03145","BK1530","01783","03315","03738","HK0000252160.HKD","BK1161","01809","01164","BK1596","02105","BK1110","SG9999015952.SGD","BK1219","01167","02511","02627","BK1521","06682","BK1148","BK1230","SG9999004220.SGD","LU2476274720.SGD","00363","02279","LU1634259391.SGD","BK1188","06608","BK1595"],"gpt_icon":0},{"id":"2584939643","title":"CStone Pharmaceuticals (SEHK:2616) Valuation Spotlight After Key Pipeline Advances and IND Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939643","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939643?lang=en_us&edition=fundamental","pubTime":"2025-11-17 14:12","pubTimestamp":1763359927,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) is in focus after two important pipeline updates landed this week. The company will showcase preclinical data for its CS2015 antibody at ACAAI 2025. In addition, CS2009 has cleared an IND milestone in China.\nSee our latest analysis for CStone Pharmaceuticals.\nCStone’s share price has surged 148% year-to-date and delivered an exceptional 227% total shareholder return over the past year. This performance has been fueled in recent days by promising advances in...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-spotlight-after-ke","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-spotlight-after-ke","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","02616","DCF","BK1161"],"gpt_icon":0},{"id":"1111247082","title":"Executive Director Yang Jiansheng Increases Stake in CStone Pharma-B (02616) by 117,500 Shares at Average Price of HK$5.42 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1111247082","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111247082?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:30","pubTimestamp":1763119855,"startTime":"0","endTime":"0","summary":"According to the latest disclosure from the Hong Kong Stock Exchange, on November 13, Executive Director Yang Jiansheng purchased an additional 117,500 shares of CStone Pharma-B (02616) at an average...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"1104226063","title":"HK Movers | Biomedical Stocks Jump With CStone Pharmaceuticals up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104226063","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104226063?lang=en_us&edition=fundamental","pubTime":"2025-11-14 10:24","pubTimestamp":1763087071,"startTime":"0","endTime":"0","summary":"Biomedical stocks jumped in Hong Kong. CStone Pharmaceuticals rose 13%; Ascletis Pharma rose 11%; Sirnaomics rose 9%; Laekna rose 7%; PegBio Co rose 6%; Immunotech Biopharm rose 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5d27790606b64b3231c65f4df87c0e89","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","02257","02105","01672","06978","02616"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":0.0794},{"period":"1month","weight":0.1087},{"period":"3month","weight":-0.388},{"period":"6month","weight":0.3362},{"period":"1year","weight":1.3359},{"period":"ytd","weight":1.6609}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CStone Pharmaceuticals is a biopharmaceutical investment holding company focused on the research and development of anti-cancer therapies. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, sale of pharmaceutical products and provision of license of its intellectual property (IP) or commercialization license. The Company’s main products include targeted therapies, AYVAKIT (avapritinib) and GAVRETO (pralsetinib). The Company is also involved in the development and commercialization of immuno-oncology. The Company mainly conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.062298},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039956},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.10478},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.048094},{"month":5,"riseRate":0.5,"avgChangeRate":0.100514},{"month":6,"riseRate":0.714286,"avgChangeRate":0.09443},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05639},{"month":8,"riseRate":0.428571,"avgChangeRate":0.079119},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.071005},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.571429,"avgChangeRate":0.024398}],"exchange":"SEHK","name":"CSTONE PHARMA-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CSTONE PHARMA-B(02616) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CSTONE PHARMA-B,02616,CSTONE PHARMA-B股票,CSTONE PHARMA-B股票老虎,CSTONE PHARMA-B股票老虎国际,CSTONE PHARMA-B行情,CSTONE PHARMA-B股票行情,CSTONE PHARMA-B股价,CSTONE PHARMA-B股市,CSTONE PHARMA-B股票价格,CSTONE PHARMA-B股票交易,CSTONE PHARMA-B股票购买,CSTONE PHARMA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CSTONE PHARMA-B(02616) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}